If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
65
results.
Updated on
16/09/2026 [06:45:00]
Results 50 to 65 of 65
Absstract of: WO2026174182A1
Pyrazolopyrimidines and imidazopyrazine compounds of Formulas (I) and (II) are provided. The compounds can be used to target OTU domain-containing protein 7A (OTUD7A), e.g., to block and/or reduce OTUD7A-mediated deubiquitination of Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 transcription factor (EWS-FLI1). Methods of treating conditions dependent on FLI1, including Ewing sarcoma, leukemia, and other cancers, by administering the compounds, are also described.
Absstract of: WO2026171195A1
The present invention provides a pharmaceutical composition comprising a piperidine ring compound, and a use thereof. Specifically provided is a pharmaceutical composition, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and CHOP or CHOEP. The pharmaceutical composition provided by the present invention has synergistic advantages, and has good therapeutic efficacy against lymphoma.
Absstract of: WO2026174042A1
Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Absstract of: WO2026173613A2
The present disclosure provides nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma. The present disclosure also provides engineered immune cells comprising nanobody-based chimeric antigen receptors (CARs) that include nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma.
Absstract of: US20260242503A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Absstract of: US20260242496A1
0000 An aqueous pharmaceutical formulation having improved stability includes denosumab and a poloxamer, and preferably a histidine buffer and/or sugar or sugar alcohol. The formulation is for use in treating or preventing osteoporosis, loss of bone mass, skeletal-related events associated with multiple myeloma, solid tumor bone metastases, giant cell tumors of the bone or hypercalcemia.
Absstract of: WO2026172270A1
A method of impairing cancer cell growth in a mammal having leukemia or lymphoma is disclosed, the method including administering to the mammal a pharmaceutical composition comprising a pharmacologically active amount of (+)-BAY K8644 as a monotherapy or in combination with the tyrosine kinase inhibitor, Ibrutinib.
Absstract of: US20260242870A1
This disclosure provides methods for imaging of samples for diagnosis of lymphoid neoplasms, lymphocytic autoimmune disease, and other conditions related to clonal expansion of lymphocytes. Using these methods, individual lymphocytes can be imaged in situ to determine tissue-wide clonality based on rearrangement of T cell receptor gene segments. Post hoc bulk sequencing allows for complementarity determining sequences to be mapped back to individual lymphocyte clones in super resolution images. In additional to its clinical applications in histopathology, these methods are also useful for the study of cellular and immunologic processes related to lymphoproliferative and autoimmune disorders.
Absstract of: AU2025227271A1
This application pertains to the use of Compound (A): or a pharmaceutically acceptable salt thereof, for the treatment of various diseases or disorders, including, for example, advanced non-Hodgkin lymphoma (NHL), relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), transformed follicular lymphoma, nodal T-follicular helper cell lymphoma (nTFHL), relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma, nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL- Al) / advanced angioimmunoblastic T-cell lymphoma (AITL), or relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL-AI) / angioimmunoblastic T-cell lymphoma (AITL).
Absstract of: US20260242391A1
Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, intreating a subject suffering from myelodysplastic syndromes (MDS), and in slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
Absstract of: US20260241033A1
The present disclosure is directed to CRISPR-related systems and components for targeting, editing, and/or modulating expression of a FLI-1 (Friend virus leukemia integration 1 transcription factor; Fli-1 Proto-Oncogene, ETS Transcription Factor) gene. The present disclosure also relates to methods and applications thereof in connection with engineered cells including T cells or T cell precursors.
Absstract of: US20260241027A1
0000 The present disclosure discloses a use of anti-CD20 ADC in the preparation of a drug for treating NHL, and the drug has excellent clinical efficacy and safety in treating a R/R NHL patient after receiving at least two standard treatments.
Absstract of: WO2025080911A1
The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.
Absstract of: WO2025080543A1
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
Nº publicación: GB2704112A 19/08/2026
Applicant:
GREY WOLF THERAPEUTICS LTD [GB]
Grey Wolf Therapeutics Limited
Absstract of: GB2704112A
A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. B is NR6R7, wherein R6 and R7 are linked to form a polycyclic group containing at least one spiro carbon, and which polycyclic group optionally contains one or more groups independently selected from NR35, CO, O, S, SO and SO2, and is optionally further substituted by one or more R5 groups; each R5 is independently selected from COOH, CONR8R9, CONHSO2R10, NR30R31, CO2-alkyl, OH, alkyl, halo, haloalkyl, alkoxy, aminoalkyl, and hydroxyalkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)-2,4-dioxo-1,3,7-triazaspiro4,5decane-7-sulfonamide No Figure
BOPI
Electronic site
